We might be able to improve the outcomes of R/R MM patients with extramedullary disease who respond to anti-BCMA CAR T cell therapy by bridging to transplantation or radiotherapy before further disease progression. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.